

Supplemental Digital Content 1. Main ARVs and ARVcs administered at ART initiation and during follow-up.

ARVs and ARVcs	Exposure in patients with diabetes (n=53)				Exposure in patients with no diabetes (n=1,541)			
	At ART initiation	Never	<1 year	≥1 year	At ART initiation	Never	<1 year	≥1 year
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Tenofovir disoproxil fumarate	12 (23)	35 (66)	6 (11)	12 (23)	477 (31)	639 (41)	95 (6)	807 (52)
Zidovudine	19 (36)	16 (30)	11 (21)	26 (49)	523 (34)	586 (38)	222 (14)	733 (48)
Stavudine	25 (42)	25 (47)	1 (2)	27 (51)	540 (35)	885 (57)	78 (5)	578 (38)
Didanosine	10 (19)	43 (81)	1 (2)	9 (17)	99 (6)	1,331 (86)	41 (3)	169 (11)
Emtricitabine	12 (23)	37 (70)	5 (9)	11 (21)	473 (31)	787 (51)	83 (5)	671 (44)
Lamivudine	31 (59)	11 (21)	4 (8)	38 (71)	970 (63)	127 (8)	233 (15)	1,181 (77)
Efavirenz	20 (37)	18 (34)	10 (19)	25 (47)	597 (39)	652 (42)	167 (11)	46 (47)
Nevirapine	22 (42)	26 (49)	5 (9)	22 (41)	706 (46)	776 (50)	172 (11)	593 (39)

Ritonavir	2 (4)	35 (66)	6 (11)	12 (23)	161 (11)	1,032 (67)	103 (7)	406 (26)
<hr/>								
ARVcs								
<hr/>								
ddI+d4T	9 (17)	44 (83)	1 (2)	8 (15)	68 (4)	1,473 (95)	4 (1)	64 (4)
d4T+3TC+EFV	0 (0)	49 (92)	2 (4)	2 (4)	37 (2)	1,420 (92)	41 (3)	80 (5)
d4T+3TC+NVP	13 (24)	35 (66)	2 (4)	16 (30)	426 (28)	1,058 (69)	97 (6)	386 (25)
TDF+3TC+EFV	0 (0)	50 (94)	2 (4)	1 (2)	4 (<1)	1,184 (77)	146 (9)	211 (14)
TDF+FTC+EFV	10 (19)	39 (74)	8 (15)	6 (11)	381 (25)	988 (64)	99 (6)	454 (30)
TDF+FTC+NVP	2 (4)	49 (92)	2 (4)	2 (4)	90 (6)	1,370 (89)	44 (3)	127 (8)
TDF+FTC+IDV/r	0 (0)	48 (91)	4 (7)	1 (2)	0 (0)	1,472 (96)	20 (1)	49 (3)
ZDV+3TC+EFV	9 (16)	33 (62)	7 (13)	13 (25)	152 (10)	1,218 (79)	106 (7)	217 (14)
ZDV+3TC+NVP	7 (13)	39 (74)	8 (15)	6 (11)	189 (12)	1,109 (72)	135 (9)	297 (19)
ZDV+3TC+IDV/r	2 (4)	46 (87)	3 (6)	4 (7)	89 (6)	1,336 (87)	62 (4)	143 (9)

Abbreviations: ARV, antiretroviral; ARVc, antiretroviral combination; ddI, didanosine; d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine; IDV/r, ritonavir boosted indinavir; ZDV, zidovudine.

Supplemental Digital Content 2. Baseline characteristics of the subanalysis.

Characteristics	Exposure to first line regimen containing				<i>p</i> -value ^b
	Tenofovir disoproxil	Zidovudine	Stavudine ^a	Didanosine + stavudine	
	fumarate				
	n (%) or median (IQR)	n (%) or median (IQR)	n (%) or median (IQR)	n (%) or median (IQR)	
Gender					< 0.001
Female	190 (58)	100 (68)	29 (83)	10 (100)	
Male	139 (42)	46 (32)	6 (17)	0 (0)	
Age (years)					< 0.001
<30	55 (17)	66 (45)	18 (51)	6 (60)	
≥30	274 (83)	80 (55)	17 (49)	4 (40)	
Body mass index (kg/m ²)					0.09
<25	284 (86)	121 (82)	34 (97)	10 (100)	
≥25	45 (14)	25 (18)	1 (3)	0 (0)	

Hepatitis B surface antigen (n=512)					0.02
Positive	2 (1)	5 (4)	2 (6)	0 (0)	
Negative	327 (99)	138 (96)	29 (94)	9 (100)	
Hepatitis C antibody (n=509)					< 0.001
Positive	0 (0)	11 (8)	3 (11)	1 (10)	
Negative	328 (100)	132 (92)	25 (89)	9 (90)	
Triglycerides (mg/dL) (n=433)					0.58
<140	184 (56)	56 (54)	2 (100)	-	
≥140	143 (44)	48 (46)	0 (0)	-	
Total cholesterol (mg/dL) (n=431)					0.56
<160	160 (49)	53 (51)	2 (100)	-	
≥160	164 (51)	52 (49)	0 (0)	-	
HIV RNA load (log ₁₀ copies/mL) (n=508)					0.68

<5	209 (64)	83 (59)	23 (67)	3 (75)	
≥5	120 (36)	58 (41)	11 (33)	1 (25)	
<hr/>					
CD4 count (cells/mm ³) (n=514)					0.91
<200	235 (72)	106 (74)	25 (74)	7 (70)	
≥200	93 (28)	36 (26)	9 (26)	3 (30)	
<hr/>					
CDC stage					0.88
A	193 (59)	84 (58)	22 (63)	5 (50)	
B or C	136 (41)	62 (42)	13 (37)	5 (50)	
<hr/>					

Abbreviations: IQR, interquartile range; CDC, Centers for Disease Control and Prevention.

Note: The number of patients is specified in case of missing data.

^aExcluding patients on didanosine + stavudine.

^bFrom Fisher's exact tests

Supplemental Digital Content 3. Association between NRTI-containing first line regimens and the occurrence of diabetes during follow-up (subanalysis).

First line regimen containing	Diabetes	Total	Unadjusted Analysis		Adjusted Analysis ^a	
			HR (95% CI)	<i>p</i> -value	aHR (95% CI)	<i>p</i> -value
Tenofovir disoproxil fumarate	3	329	1		1	
Zidovudine	6	146	4.9 (1.2, 19.7)	0.03	6.6 (1.6, 27.5)	0.01
Stavudine ^b	1	35	6.0 (0.6, 58.3)	0.12	9.4 (0.9, 95.1)	0.06
Didanosine+stavudine	3	10	22.4 (4.0, 126.6)	< 0.001	73.2 (11.5, 465.2)	< 0.001

Abbreviation: HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio.

^aAdjusted for gender, age, hepatitis B surface antigen and hepatitis C antibody.

^bExcluding patients on didanosine + stavudine.